GSA Capital Partners LLP bought a new position in shares of CureVac N.V. (NASDAQ:CVAC - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 307,941 shares of the company's stock, valued at approximately $853,000. GSA Capital Partners LLP owned 0.14% of CureVac as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of CVAC. Greenleaf Trust purchased a new stake in CureVac in the 1st quarter valued at $31,000. Two Sigma Advisers LP purchased a new stake in CureVac in the 4th quarter valued at $48,000. Jump Financial LLC purchased a new stake in CureVac in the 4th quarter valued at $55,000. D. E. Shaw & Co. Inc. purchased a new stake in CureVac in the 4th quarter valued at $66,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in CureVac by 14.3% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,125 shares of the company's stock valued at $81,000 after buying an additional 3,648 shares during the last quarter. 17.26% of the stock is owned by institutional investors and hedge funds.
CureVac Stock Up 0.4%
Shares of NASDAQ:CVAC opened at $5.41 on Friday. The company has a market capitalization of $1.21 billion, a PE ratio of 5.88 and a beta of 2.53. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.65 and a quick ratio of 7.64. The business has a fifty day moving average price of $5.17 and a two-hundred day moving average price of $3.99. CureVac N.V. has a 1 year low of $2.37 and a 1 year high of $5.72.
CureVac (NASDAQ:CVAC - Get Free Report) last announced its quarterly earnings data on Thursday, May 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.08). The business had revenue of $0.94 million during the quarter, compared to the consensus estimate of $4.27 million. CureVac had a net margin of 35.44% and a return on equity of 30.89%. Analysts forecast that CureVac N.V. will post 0.72 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on CVAC shares. UBS Group lowered CureVac from a "strong-buy" rating to a "neutral" rating and lowered their price target for the company from $12.00 to $5.50 in a research report on Thursday, June 26th. Citigroup lowered CureVac to a "market perform" rating in a research report on Thursday, June 12th. JMP Securities reissued a "market outperform" rating and issued a $10.00 price target on shares of CureVac in a research report on Wednesday, May 28th. Jefferies Financial Group restated a "hold" rating and issued a $5.00 price objective (down previously from $7.00) on shares of CureVac in a research note on Friday, June 13th. Finally, Citizens Jmp downgraded CureVac from a "strong-buy" rating to a "hold" rating in a research note on Thursday, June 12th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $6.83.
Get Our Latest Stock Report on CureVac
CureVac Company Profile
(
Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
